Drug intelligence / Profile preview

IVL4002

Development stage: Phase 1
Lead developer: Inventage Lab
Modality: Nanoparticles → Drug Delivery Systems, Small Molecules
Administration: Injectable

Overview

IVL4002 is a novel long-acting injectable drug formulation developed by Inventage Lab. It consists of monodisperse microspheres encapsulating an FDA-approved small molecule drug that was identified through drug repurposing. The specific active pharmaceutical ingredient within IVL4002 has not been publicly disclosed, but the formulation aims to provide sustained release and improved pharmacokinetics for indications in immune system diseases and nervous system diseases. As of early 2025, IVL4002 is in preclinical development, with ongoing studies evaluating its safety and pharmacokinetic profile.

Beyond the preview

Go deeper on IVL4002.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on IVL4002.

Explore the full profile